fr

CARMAT receives FDA conditional approval to initiate the second cohort of the EFS study in the United States

Approval of the resolutions pertaining to the reserved capital increase and the Group's governance

Download

€50M Equity Financing to Reinforce CARMAT’s Cash Resources

Download

2015 annual results

Download

Information regarding the Feasibility study of the CARMAT bioprosthetic artificial heart

Download

Update on the Feasibility study of its bioprosthetic artificial heart

Download

Q&A on CARMAT project

Download

CARMAT obtains regulatory approval to finalize its Clinical Feasibility Study

Download

2015 half-year results in line with the Company's stage of development

Download
Top of page